妊娠期子痫前期筛查:美国预防服务工作组推荐声明
本推荐声明由美国预防服务工作组(USPSTF)更新1996年子痫前期筛查推荐。USPSTF回顾了子痫前期筛查与诊断试验准确性、筛查利弊、风险预测工具效果及筛查检出后治疗利弊的证据。基于治疗可降低母儿患病率和死亡率、血压测量准确性已确立,USPSTF发现筛查子痫前期对母婴有显著获益,且筛查与治疗的危害不超过小程度,结论为中等确定性净获益显著。最终推荐孕妇在整个孕期通过血压测量筛查子痫前期(B级推荐)。
要点
- USPSTF推荐孕妇在整个孕期通过血压测量筛查子痫前期(B级推荐)。
- USPSTF以中等确定性认定孕妇子痫前期筛查净获益显著。
- 筛查与治疗的危害被评定为不超过小程度。
- 子痫前期影响约4%的美国妊娠,是全球孕产妇死亡第二大原因。
- 非裔美国女性子痫前期患病率高于白人女性,相关病死率是白人女性的3倍。
适用人群与场景
- 孕妇,在整个孕期进行子痫前期筛查。
处置流程与药物剂量
- 在整个孕期通过血压测量筛查子痫前期(USPSTF B级推荐)。
研究设计与关键结果
- USPSTF回顾了子痫前期筛查与诊断试验准确性、筛查利弊、风险预测工具效果及筛查检出后治疗利弊的证据。
- 基于治疗可降低母儿患病率和死亡率及血压测量准确性已确立,USPSTF发现筛查子痫前期对母婴有显著获益。
- 有充分证据将筛查与治疗的危害限定为不超过小程度。
- USPSTF以中等确定性结论:孕妇子痫前期筛查净获益显著。
证据类型、等级与局限
- 证据类型:USPSTF推荐声明(指南)。
- 推荐等级:B级推荐。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对孕妇在整个孕期进行血压测量以筛查子痫前期(USPSTF B级推荐)。
指南或共识出处
- 美国预防服务工作组(USPSTF)推荐声明:妊娠期子痫前期筛查,更新1996年推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth.
SUBPOPULATION CONSIDERATIONS: Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute to poor outcomes associated with preeclampsia in African American women.
OBJECTIVE: To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia.
EVIDENCE REVIEW: The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia.
FINDINGS: Given the evidence that treatment can reduce maternal and perinatal morbidity and mortality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial benefit for the mother and infant. In addition, there is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greater than small. Therefore, the USPSTF concludes with moderate certainty that there is a substantial net benefit of screening for preeclampsia in pregnant women.
CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. (B recommendation).
参考来源
- Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA. 2017. PMID: 28444286. doi:10.1001/jama.2017.3439
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。